| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |